The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors

Author(s): John R. Woolfrey, G. Scott Weston

Journal Name: Current Pharmaceutical Design

Volume 8 , Issue 17 , 2002

Become EABM
Become Reviewer
Call for Editor


The recent success of the first FDA-approved small-molecule tyrosine kinase inhibitor Gleevec (STI-571, imatinib mesylate) in the treatment of chronic myelogenous leukemia (CML) has focused attention on the potential therapeutic usefulness of inhibitors of other kinase targets. This review shall highlight recent applications of computational chemistry methods, comprising both ligand-based and structure-based approaches, in the discovery and design of kinase inhibitors. In particular, we will focus on ATP-competitive inhibitors of selected kinase targets of therapeutic importance.

Keywords: kinase inhibitor, gleevec, imatinib mesylate, cml, chronic myelogenous leuremig, comfa, comsia

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Published on: 01 March, 2012
Page: [1527 - 1545]
Pages: 19
DOI: 10.2174/1381612023394304
Price: $65

Article Metrics

PDF: 8